Circular RNAs signature predicts the early recurrence of stage III gastric cancer after radical surgery.
about
Polymorphisms and expression pattern of circular RNA circ-ITCH contributes to the carcinogenesis of hepatocellular carcinoma.CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630.Circ-104916 is downregulated in gastric cancer and suppresses migration and invasion of gastric cancer cells.Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271.Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expressionCircular RNAs: A novel type of biomarker and genetic tools in cancer.Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway.Circular RNAs: emerging cancer biomarkers and targets.Circular RNAs (circRNAs) in Health and Disease.Circular RNAs in cancer: opportunities and challenges in the field.Circular RNAs: Biogenesis, Function, and a Role as Possible Cancer Biomarkers.Analysis of co-expression networks for circular RNAs and mRNAs reveals that circular RNAs hsa_circ_0047905, hsa_circ_0138960 and has-circRNA7690-15 are candidate oncogenes in gastric cancer.Circular RNAs: clinical relevance in cancer.The expression of circRNAs as a promising biomarker in the diagnosis and prognosis of human cancers: a systematic review and meta-analysis.Identification of the tumor-suppressive function of circular RNA ITCH in glioma cells through sponging miR-214 and promoting linear ITCH expression.Circular RNAs in Cancer - Lessons Learned From microRNAs.circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinomaCirc_0027599/PHDLA1 suppresses gastric cancer progression by sponging miR-101-3p.1The emerging role of circular RNAs in gastric cancerCircular RNAs: Promising Biomarkers for Human DiseasesRegulatory network of circRNA-miRNA-mRNA contributes to the histological classification and disease progression in gastric cancer
P2860
Q40163580-95F9C672-20FF-413C-B25A-47898E6D8944Q41008499-448AD5C4-BE4E-4D4B-9C78-CA514B4F1774Q41097087-9D8B9144-F24E-4EF5-91C9-917D88BD671BQ41098294-6843D47F-81C3-4F2D-9E89-E939BE551E05Q41279168-35499789-2150-4902-A341-D86C2F6B93BBQ42177829-F9DDA1BE-5B23-4C69-B0CA-04E249D6CBDDQ42668992-8A49A128-B305-40B3-9BF0-16708227BE7BQ45130199-EE3AD4B1-5CF4-4022-8864-A0862F2C7BEDQ46252873-D570FEA7-FB83-48F9-83E7-243BADF7D9B2Q47908310-FEF53197-0C5E-464D-864C-0E370F71D133Q48213837-BF9505F7-E6F8-442A-AA70-5822294DE2DCQ49584324-CC18BC4C-39E7-479F-A639-D6B3823CE2F8Q50128135-AAE09B38-2F6E-43A5-8B17-38649236A4EBQ52652998-2FF46950-CF21-42E1-AE7E-7A891D69D2D8Q55005059-77A2057E-89A7-4C14-BDC2-25D82A2F54D3Q55401342-BFCD0E13-B71C-44D2-B1E4-DD7A97A32542Q58553877-5626A2F0-CDAA-4387-B06F-CB0637ED2732Q58605959-F4327ABC-0383-484C-8978-EA9F73C52EDEQ58790052-F0F992E5-149A-47A7-B173-C823703EFFB3Q58802897-D2CFF9F7-7C45-49A2-A2AB-CF719377F455Q58803902-102C31EF-19C4-4D76-9235-D60A2EB798CA
P2860
Circular RNAs signature predicts the early recurrence of stage III gastric cancer after radical surgery.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Circular RNAs signature predic ...... cancer after radical surgery.
@ast
Circular RNAs signature predic ...... cancer after radical surgery.
@en
type
label
Circular RNAs signature predic ...... cancer after radical surgery.
@ast
Circular RNAs signature predic ...... cancer after radical surgery.
@en
prefLabel
Circular RNAs signature predic ...... cancer after radical surgery.
@ast
Circular RNAs signature predic ...... cancer after radical surgery.
@en
P2093
P2860
P356
P1433
P1476
Circular RNAs signature predic ...... c cancer after radical surgery
@en
P2093
Tingyu Mou
Xiaolong Qi
Zhiyong Shen
P2860
P304
22936-22943
P356
10.18632/ONCOTARGET.15288
P407
P50
P577
2017-04-01T00:00:00Z